An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
Clinical trial NCT05798117 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05798117
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-28
- Primary completion
- 2026-09-24
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.